洛铂术中灌注化疗辅助治疗中晚期结肠癌的效果  

Effect of Intraoperative Perfusion Chemotherapy with Lobaplatin in Adjuvant Treatment of Middle and Advanced Colon Cancer

作　　者：檀家俊 周春根 陈正鑫 徐俊华[1] 朱勇[1] TAN Jiajun;ZHOU Chungen;CHEN Zhengxin;XU Junhua;ZHU Yong(Anorectal Center,Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210022,China;不详)

机构地区：[1]南京中医药大学附属南京中医院(南京市中医院)肛肠中心,江苏南京210022

出　　处：《中国医学创新》2025年第5期61-64,共4页Medical Innovation of China

摘　　要：目的:分析洛铂术中灌注化疗辅助治疗中晚期结肠癌的效果。方法:以南京中医药大学附属南京中医院肛肠中心2022年1-12月收治的80例中晚期结肠癌患者为研究对象,并随机分为常规组(n=40,腹腔镜结肠癌根治术联合辅助化疗)和观察组(n=40,常规组基础上联合洛铂灌注化疗)。对比两组总住院时长、术后并发症发生率、化疗不良反应发生率及肿瘤标志物水平。结果:两组术后并发症发生率、化疗不良反应发生率及总住院时长比较,差异均无统计学意义(P>0.05)。治疗后观察组癌胚抗原(CEA)水平显著低于常规组(P<0.05)。治疗后,两组糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)比较,差异均无统计学意义(P>0.05)。结论:洛铂术中灌注化疗辅助治疗中晚期结肠癌不会增加术后并发症、化疗不良反应发生风险,可更有效地下调肿瘤标志物水平。Objective:To analyze the effect of intraoperative perfusion chemotherapy with Lobaplatin in adjuvant treatment of middle and advanced colon cancer.Method:A total of 80 patients with middle and advanced colon cancer admitted to Anorectal Center,Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine from January to December 2022 were selected as the study objects,and were randomly divided into the conventional group(n=40,laparoscopic radical resection of colon cancer combined with adjuvant chemotherapy)and the observation group(n=40,combined with perfusion chemotherapy with Lobaplatin on the basis of conventional group).The total length of hospital stay,the incidence of postoperative complications,the incidence of chemotherapy adverse reactions and the levels of tumor markers were compared between the two groups.Result:There were no comparative difference in the incidence of postoperative complications,the incidence of chemotherapy adverse reactions and the total length of hospital stay between the two groups(P>0.05).After treatment,the carcinoembryonic antigen(CEA)level in observation group was significantly lower than that in conventional group(P<0.05).After treatment,there were no significant differences in carbohydrate antigen 19-9(CA19-9)and alpha-fetoprotein(AFP)between the two groups(P>0.05).Conclusion:Intraoperative perfusion chemotherapy with Lobaplatin in adjuvant treatment of middle and advanced colon cancer does not increase the risk of postoperative complications and chemotherapy adverse reactions,and can more effectively down-regulate the levels of tumor markers.

关 键 词：结肠癌 腹腔镜结肠癌根治术 洛铂 灌注化疗 

分 类 号：R735.35[医药卫生—肿瘤]